Introduction
============

*Mycobacterium tuberculosis* is one of the most successful human pathogens, contributing to the deaths of ∼2 million people per annum by causing tuberculosis ([@B1]). It is an adaptable bacterium capable of survival in its preferred environment, the interior of a macrophage ([@B2]), and within droplet nuclei in the atmosphere that are produced by infected individuals. The disease is spread by inhalation of such droplets, and following initial infection, *M. tuberculosis* can persist in a nonreplicating state from which it may emerge when conditions are more favorable (*e.g.* when the immune system is suppressed), a phenomenon known as reactivation tuberculosis ([@B3]). This strategy has been so successful that the reservoir of infection is thought to be as great as one-third of the world\'s population ([@B1]), and thus the potential for reactivation tuberculosis is very large.

Appropriate gene regulation is likely to be vital for establishing and emerging from the dormant state. The presence of \>100 regulator proteins, 11 two-component systems, 6 serine-threonine protein kinases, and 13 alternative σ factors ([@B4]) suggests that transcription regulation is important for *M. tuberculosis* pathogenesis. Cyclic AMP is likely to be an important signaling molecule in *M. tuberculosis* because it is predicted to possess 17 genes encoding adenylyl cyclases ([@B4]), at least one of which, Rv0386, is required for virulence ([@B5]). Interestingly, cAMP levels increase upon infection of macrophages by pathogenic mycobacteria ([@B6], [@B7]), and furthermore, addition of cAMP to cultures of *M. tuberculosis* causes changes in gene expression ([@B8]). Recently, Bishai and co-workers ([@B5]) showed that upon infection of macrophages, a bacterially derived cAMP burst promotes bacterial survival by interfering with host signaling pathways, but as well as influencing host regulatory networks, cAMP is also important in bacterial gene regulation.

The best characterized bacterial cAMP-responsive transcriptional regulator is the Escherichia coli cyclic AMP receptor protein (CRP,[^2^](#FN3){ref-type="fn"} sometimes known as catabolite gene activator protein). E. coli CRP is activated by binding cAMP and controls aspects of carbon metabolism and virulence gene expression and may act as a more general chromosome organizer ([@B9][@B10][@B11]). In E. coli under conditions of glucose starvation, intracellular cAMP concentrations increase via a mechanism involving interactions between the glucose phosphotransferase system transporter and adenylyl cyclase ([@B12]). Cyclic AMP is bound by the E. coli CRP dimer resulting in enhanced recognition of a specific DNA sequence (TGTGANNNNNNTCACA) present within the promoter regions of target genes ([@B13]). At activated promoters, CRP recruits RNA polymerase (RNAP) and promotes transcription by establishing specific protein-protein contacts ([@B10], [@B14]).

The *M. tuberculosis* Rv3676 protein (hereafter CRP*^Mt^*) is a member of the CRP family ([@B15][@B16][@B17]). CRP*^Mt^* is 32% identical (53% similar) over 189 amino acids to E. coli CRP ([@B16]). Like CRP in E. coli, CRP*^Mt^* is a global transcriptional regulator because a deletion mutant has altered transcription of a large number of genes ([@B16]). Moreover, it is implicated in the virulence of *M. tuberculosis* because the CRP*^Mt^* mutant is attenuated for growth in mice and macrophages as well as *in vitro* ([@B16]). Polymorphisms in CRP that enhance DNA binding have also occurred in the Bacillus Calmette-Guérin vaccine strain of *Mycobacterium bovis* ([@B18][@B19][@B20]) and result in changes in transcription of a number of genes, which, although not contributing to the attenuation of Bacillus Calmette-Guérin, may have been selected by growth *in vitro* ([@B20]).

In the CRP*^Mt^* mutant, the largest decreases in expression were for the *rpfA* and *whiB1* genes ([@B16]). *In vivo* and *in vitro* analyses indicated that CRP*^Mt^* activates expression of *rpfA* and *whiB1* ([@B16], [@B17]). These are potentially significant observations because *rpfA* encodes a protein that is thought to be involved in reviving dormant bacteria ([@B21]), and *whiB1* encodes a Wbl family protein ([@B22]). Wbl proteins are found only in actinomycetes and bind redox-sensitive iron-sulfur clusters ([@B23], [@B24]). The mechanism(s) of action of Wbl proteins is still unclear; some have been reported to have protein-disulfide reductase activity ([@B24]), and at least one (WhiB3) has been shown to bind DNA ([@B25]), consistent with the suggestion that Wbl proteins are transcription factors that might function in the control of developmental processes ([@B22], [@B26]). This latter suggestion raises the possibility that CRP*^Mt^* in complex with cAMP regulates genes involved in the developmental switch associated with *M. tuberculosis* persistence and/or emergence from the dormant state. However, previous work suggested that although CRP*^Mt^* binds cAMP, this interaction induces a relatively small enhancement in specific DNA binding ([@B15][@B16][@B17]). Thus, there are differences between E. coli CRP, where the presence of cAMP enhances specific DNA binding by several orders of magnitude ([@B27]), and CRP*^Mt^*. Hence, the aim of this work was to investigate the interaction between CRP*^Mt^* and cAMP and determine the mechanism of CRP*^Mt^*-mediated activation of *whiB1* expression. Here, the following points are shown: (i) CRP*^Mt^* dimer binds two molecules of cAMP; (ii) unlike E. coli CRP, the CRP*^Mt^* cAMP-binding sites do not interact; (iii) CRP*^Mt^* binds at two immediately adjacent sites in the *whiB1* promoter; and (iv) occupation of the upstream CRP*^Mt^*-binding site at low cAMP concentrations activates *whiB1* transcription at a step after open complex formation, whereas occupation of the downstream site at high cAMP concentrations antagonizes activation from the upstream site by preventing open complex formation. In addition, a molecular model based on the E. coli CRP structure provides a plausible explanation for the distinctive cAMP binding properties of CRP*^Mt^*.

EXPERIMENTAL PROCEDURES
=======================

### 

#### Bacterial Strains, Plasmids, and Growth Conditions

Bacterial strains and plasmids are listed in [Table 1](#T1){ref-type="table"}. E. coli cultures were grown in Luria-Bertani (LB) medium ([@B36]) in a 1:5 volume/flask ratio at 37 °C with shaking at 250 rpm, except for *in vivo* transcription experiments where strains were grown in a 1:25 volume/flask ratio. Where required, antibiotics were added to media at the following concentrations: tetracycline 35 μg ml^−1^, kanamycin 50 μg ml^−1^, ampicillin 100 μg ml^−1^. *M. tuberculosis* cultures (100 ml) were grown in 1 liter of polycarbonate culture bottles (Techmate) in a Bellco roll-in incubator (2 rpm) at 37 °C in Dubos broth containing 0.05% (v/v) Tween 80 supplemented with 0.2% (v/v) glycerol and 4% Dubos medium albumin. Where required, kanamycin was added at a final concentration of 25 μg ml^−1^. *Mycobacterium smegmatis* was grown to log phase (56 h) in LB medium in a 1:5 volume/flask ratio at 37 °C with shaking at 250 rpm.

###### 

**Bacterial strains and plasmids**

IPTG is isopropyl 1-thio-β -[d]{.smallcaps}-galactopyranoside.

  Strain or plasmid                   Relevant characteristics                                                                                                Source or Ref.
  ----------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------
  E. coli strains                                                                                                                                             
      BL21 (λDE3)                     Lysogen of λDE3 carrying a copy of the T7 RNAP under the control of the IPTG-inducible *lacUV5* promoter                Novagen
      JRG5876                         BL21 (λDE3) Δ*cyaA*; kan^R^                                                                                             This work
      JRG6015                         JRG5876 pGS2132                                                                                                         This work
      M182                            E. coli K12 Δ*lac*                                                                                                      [@B28]
      JRG2630                         M182 Δ *crp* derivative                                                                                                 [@B29]
      JRG5875                         M182 Δ*crp*Δ*cyaA*                                                                                                      This work
      JRG6016                         JRG2630 p2130 ptac85                                                                                                    This work
      JRG6017                         JRG2630 p2130 pGS1645                                                                                                   This work
      JRG6018                         JRG5875 p2130 ptac85                                                                                                    This work
      JRG6019                         JRG5875 p2130 pGS1645                                                                                                   This work
                                                                                                                                                              
  *M. tuberculosis* strains                                                                                                                                   
      H37Rv                           Wild-type virulent strain                                                                                               [@B30]
      ΔRv3676                         H37Rv, deletion of *Rv3676* (CRP*^Mt^*)                                                                                 [@B16]
      H37Rv/pRB142                    H37Rv, with *whiB1-lacZ* reporter plasmid pRB142                                                                        This work
      H37Rv/pRB143                    H37Rv, with *whiB1-lacZ*reporter plasmid pRB143                                                                         This work
      H37Rv/pRB144                    H37Rv, with *whiB1-lacZ* reporter plasmid pRB144                                                                        This work
      H37Rv/pRB145                    H37Rv, with *whiB1-lacZ* reporter plasmid pRB145                                                                        This work
      H37Rv/pRB146                    H37Rv, with *whiB1-lacZ* reporter plasmid pRB146                                                                        This work
      ΔRv3676/pRB142                  ΔRv3676, with *whiB1-lacZ*reporter plasmid pRB142                                                                       This work
                                                                                                                                                              
  *M. smegmatis*strains                                                                                                                                       
      mc^2^ 155                       Source of RNAP                                                                                                          [@B31]
                                                                                                                                                              
  E. coli plasmids                                                                                                                                            
      pCR4Blunt-TOPO                  General cloning vector for blunt-ended PCR products; Ap^R^, Kan^R^                                                      Invitrogen
      pET28a                          His~6~ tag overexpression vector; Kan^R^                                                                                Novagen
      pRW50                           *lacZ* transcriptional reporter plasmid; Tet^R^                                                                         [@B32]
      ptac85                          Expression vector with an IPTG-inducible promoter; Ap^R^                                                                [@B33]
      pGS1645                         ptac85 containing *Rv3676* gene                                                                                         This work
      pGS2060                         pCR4Blunt-TOPO containing the region upstream of *whiB1*                                                                This work
      p2130                           pRW50 containing *CCgal*Δ*4*, a derivative of *galP1* with a consensus CRP-binding site centered at position −37.5 bp   [@B34]
      pGS2132                         pET28a derivative encoding His~6~-CRP*^Mt^* fusion protein; Ap^R^                                                       This work
      pGS2060                         pCR4Blunt-TOPO containing the 285-bp region upstream of *whiB1*                                                         This work
      pGS2061                         As pGS2060 but with CRP*^Mt^* site 1 altered to AGTTAGATAGCCAACG                                                        This work
      p2225                           As pGS2060 but with CRP*^Mt^* site 2 altered to CCAAACACTATTGACA                                                        This work
      p2227                           As pGS2060 but with CRP*^Mt^* site 1 and site 2 altered                                                                 This work
                                                                                                                                                              
  *M. tuberculosis*shuttle plasmids                                                                                                                           
      pEJ414                          *lacZ* transcriptional reporter plasmid; Kan^R^                                                                         E. O. Davis ([@B35])
      pRB142                          pEJ414 derivative containing transcriptional fusion of *whiB1* upstream region with *lacZ*                              This work
      pRB143                          pRB142 with mutated CRP1                                                                                                This work
      pRB144                          pRB142 with mutated CRP2                                                                                                This work
      pRB145                          pRB142 with mutated CRP1 and CRP2                                                                                       This work
      pRB146                          pRB142 with improved CRP2                                                                                               This work

#### Overproduction and Purification of CRP^Mt^

The CRP*^Mt^* (Rv3676) open reading frame was amplified by PCR using primers Myc1746 (5′-CATCATGAATTCGTGGACGAGATCCTGGCC-3′) and Myc1747 (5′-CATCATACTCGAGCACTATTACCTCGCTCGGCGGGC-3′) containing engineered EcoRI and XhoI sites, respectively. This fragment was ligated into the corresponding sites of a pET28a derivative, in which the kanamycin resistance gene had been disrupted by the insertion of an ampicillin resistance gene (*bla*). The resulting plasmid (pGS2132) encoded a His~6~-CRP*^Mt^* fusion protein. The plasmid pGS2132 was moved into E. coli strain JRG5876 (BL21 λDE3 Δ*cyaA*), for expression of the recombinant protein by addition of 1 m[m]{.smallcaps} isopropyl 1-thio-β-[d]{.smallcaps}-galactopyranoside, followed by a further 3-h growth at 37 °C before collecting the bacteria by centrifugation. The bacteria were lysed by resuspending in 20 m[m]{.smallcaps} sodium phosphate, pH 7.2, containing 0.5 [m]{.smallcaps} NaCl, followed by repeated freeze-thawing and sonication. The lysate was cleared by centrifugation, and the resulting cell-free extract was passed through a nickel-charged Hi-Trap chelating column (GE Healthcare). The recombinant His~6~-CRP*^Mt^* protein was eluted using an imidazole gradient (0--500 m[m]{.smallcaps} in 20 ml). The pooled fractions containing His~6~-CRP*^Mt^* were dialyzed in phosphate-buffered saline (137 m[m]{.smallcaps} NaCl, 2.7 m[m]{.smallcaps} KCl, 10 m[m]{.smallcaps} Na~2~HPO~4~, 2 m[m]{.smallcaps} KH~2~PO~4~), and 10% (v/v) glycerol was added to the protein before storage at −20 °C. Where indicated the His~6~ tag was removed by treatment with the protease thrombin (10 units for 16 h at 4 °C).

#### Trypsin Digestion of His~6~-CRP^Mt^

Recombinant His~6~-CRP*^Mt^* (15 μg) was incubated with 2 m[m]{.smallcaps} cAMP or cGMP for 10 min at 37 °C, followed by the addition of a second cyclic nucleotide (2 m[m]{.smallcaps}) for 10 min where indicated. The protein was then cleaved with 1 μg of trypsin (Sigma) for up to 10 min at 20 °C, and the reaction was stopped by the addition of 1.3% SDS and heating to 100 °C for 10 min. The resulting fragments were analyzed on a 15% SDS-polyacrylamide gel.

#### Isothermal Calorimetry

Recombinant His~6~-CRP*^Mt^* was extensively dialyzed against phosphate-buffered saline, and the concentration of protein was determined by SDS-PAGE and amino acid analysis (ion exchange chromatography and ninhydrin detection). The sodium salt of cAMP was dissolved in the dialysate phosphate-buffered saline, and the concentration was determined by UV absorption spectroscopy using the extinction coefficient of ϵ~260~ of 1.23 × 10^4^ [m]{.smallcaps}^−1^ cm^−1^. All samples were centrifuged prior to the titrations. The titration calorimetry measurements were performed using a MicroCal VP-ITC (MicroCal LLC, Northampton, MA). The isothermal calorimetry sample cell (cell volume 1.4 ml) was loaded with 84 μ[m]{.smallcaps} His~6~-CRP*^Mt^*. After a suitable period of thermal equilibration (25 °C), 18 injections of 15 μl of 0.87 m[m]{.smallcaps} cAMP were introduced into the protein solution every 6 min with continual stirring and an initial delay of 2 min. A small preinjection of 3 μl was also made to expel any air bubbles that may have accumulated during equilibration. In a separate control experiment, aliquots of the cAMP solution were titrated into the dialysis buffer to determine whether the ligand exhibited heat of dilution. Data analysis and fitting were done using Origin 7.0 (MicroCal LLC), and corrected binding isotherms were best fit using a single set of identical binding sites model as described by Wiseman *et al.* ([@B37]).

#### Transfer of Plasmids, Preparation of Cell-free Extracts, and Assay for β-Galactosidase in M. tuberculosis

These were carried out as described previously ([@B16]). β-Galactosidase assays on log phase cultures (*A*~600\ nm~ ∼ 0.5) were done according to Miller ([@B38]). Three independent cultures were analyzed for each strain.

#### 5′-Rapid Amplification of cDNA Ends

5′-Rapid amplification of cDNA ends was performed using the 5′-rapid amplification of cDNA ends system from Invitrogen according to the manufacturer\'s instructions. DNA-free RNA (5 μg) from *M. tuberculosis* H37Rv was reverse-transcribed with GSP1 (5′-TACGGGCTTTCGTGCG-3′) using Superscript II reverse transcriptase. The cDNA was purified on a SNAP column and tailed with dCTP using terminal deoxynucleotidyltransferase. The tailed cDNA was amplified using Platinum® Taq with primers GSP2 (5′-CGCCGCTCGTCTTCGCTCAT-3′) and AAP (5′-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3′). The product was visualized on a 1.5% agarose gel, and a band of ∼300 bp was excised and sequenced.

#### Construction of Reporter Gene Plasmids Using the Upstream Region of whiB1

The region of the DNA sequence upstream of *whiB1* was generated by PCR from *M. tuberculosis* genomic DNA using the primer pairs Myc896 (5′-GCTCTAGAGCAAGAAAGCGGATCTG-3′) and Myc487 (5′-GCAAGCTTGCCTTGTGGCGCCAATC-3′) (bp 3,595,415--3,595,731). This fragment was ligated into the XbaI and HindIII sites of the polylinker in the *lacZ* transcriptional reporter plasmid pEJ414 ([@B34]) to make pRB142 (P*whiB1*). This construct was verified by DNA sequencing.

#### Mutagenesis of CRP-binding Site in Plasmid pRB142

This was performed using the Stratagene QuikChange mutagenesis kit. To mutagenize CRP1 (AGTGAGATAGCCCACG to AGTtAGATAGCCaACG), the primers used were Myc898 (5′-AACGAGATCGCCAGAGTTAGATAGCCAACGCGCTTACGTAACAC-3′) and Myc899 (5′-GTGTTACGTAAGCGCGTTGGCTATCTAACTCTGGCGATCTCGTT-3′) to generate pRB143. To mutagenize CRP2 (CGTAACACTATTGACA to CcaAACACTATTGACA), the primers used were Myc900 (5′-TAGCCCACGCGCTTACCAAACACTATTGACATCTGTTGAGCCTG-3′) and Myc901 (5′-CAGGCTCAACAGATGTCAATAGTGTTTGGTAAGCGCGTGGGCTA-3′) to generate pRB144. To mutagenize both CRP1 and CRP2, the primers used were Myc963 (5′-CGCCAGAGTTAGATAGCCAACGCGCTTACCAAACACTATTGACATCTGTTG-3′) and Myc964 (5′-CAACAGATGTCAATAGTGTTTGGTAAGCGCGTTGGCTATCTAACTCTGGCG-3′) to generate pRB145. To improve CRP2 (CGTAACACTATTGACA to CGTgACACTATTGACA), the primers used were 5′-TAGCCCACGCGCTTACGTGACACTATTGACATCTGTTGAGCCTG-3′ and 5′-CAGGCTCAACAGATGCACATAGTGTTTGGTAAGCGCGTGGGCTA-3′. Mutagenized constructs were verified by DNA sequencing.

#### β-Galactosidase Assays in E. coli

Assays were carried out on log phase cultures (*A*~600\ nm~ ∼ 0.5) according to Miller ([@B38]). Five independent cultures were analyzed for each strain.

#### Electrophoretic Mobility Shift Assays

The region upstream of the *whiB1* gene was excised from plasmid pGS2060 using restriction enzymes XbaI and HindIII. The resulting fragment was end-labeled using 0.37 MBq of \[α-^32^P\]dGTP, dATP, and Klenow enzyme, and unincorporated radionucleotides were removed using a QIAquick PCR clean-up kit (Qiagen). Radiolabeled DNA (∼5 ng) was incubated with 0--21 μ[m]{.smallcaps} His~6~-CRP*^Mt^* (or CRP*^Mt^* where indicated) and 0--2 m[m]{.smallcaps} cAMP, in the presence of 20 m[m]{.smallcaps} HEPES, pH 7.5, 0.2 m[m]{.smallcaps} EDTA, 10 m[m]{.smallcaps} (NH~4~)~2~SO~4~, 1 m[m]{.smallcaps} dithiothreitol, 15 m[m]{.smallcaps} MgCl~2~, 15 m[m]{.smallcaps} KCl, 0.05 mg ml^−1^ bovine serum albumin, and 0.01 unit of poly(dI-dC), for 30 min at 25 °C. The resulting complexes were then separated on 6% polyacrylamide gels buffered with 0.5× TBE (45 m[m]{.smallcaps} Tris borate, 1 m[m]{.smallcaps} EDTA).

#### DNase I Footprinting

Radiolabeled *whiB1* promoter DNA, or *whiB1* promoters with mutated CRP sites (∼100 ng), was incubated with 2.5--50 μ[m]{.smallcaps} His~6~-CRP*^Mt^* in the presence of 50 m[m]{.smallcaps} Tris, pH 7.5, 100 m[m]{.smallcaps} NaCl, 10 m[m]{.smallcaps} MgCl~2~, and 2 m[m]{.smallcaps} cAMP for 30 min at 25 °C. Footprinting reactions containing RNAP were done in the presence of 40 m[m]{.smallcaps} Tris, pH 8.0, 75 m[m]{.smallcaps} KCl, 10 m[m]{.smallcaps} MgCl~2~, 0.1 m[m]{.smallcaps} EDTA, 1 m[m]{.smallcaps} dithiothreitol, and 250 μg ml^−1^ bovine serum albumin. The complexes were then digested with 1 unit of DNase I for 15--60 s at 25 °C. Reactions were stopped by the addition of 200 μl of 0.3 [m]{.smallcaps} sodium acetate, pH 5.2, containing 20 m[m]{.smallcaps} EDTA, followed by phenol/chloroform extraction. The DNA was ethanol-precipitated and resuspended in loading buffer (80% v/v formamide, 0.1% w/v SDS, 10% v/v glycerol, 8 m[m]{.smallcaps} EDTA, 0.1% w/v bromphenol blue, 0.1% w/v xylene cyanol) for electrophoretic fractionation on 6% polyacrylamide-urea gels and autoradiographic analysis. Maxam and Gilbert G tracks of the DNA fragments were used to provide a calibration ([@B39]).

#### In Vitro Transcription Reactions and Permanganate Footprinting

*M. smegmatis* RNAP was isolated by a method adapted from Beaucher *et al.* ([@B40]). A 6-g wet cell pellet of *M. smegmatis* mc^2^ 155 was disrupted by passage through a French pressure cell. The lysate was then centrifuged and subjected to ammonium sulfate precipitation. The resulting cytoplasmic extract was dialyzed against RNAP buffer (50 m[m]{.smallcaps} Tris-Cl, pH 8.0, 10 μ[m]{.smallcaps} ZnSO~4~, 1 m[m]{.smallcaps} EDTA, 10 m[m]{.smallcaps} MgCl~2~, and 20% glycerol) containing 10 m[m]{.smallcaps} KCl, before loading onto a 5-ml HiTrap heparin column (GE Healthcare). Elution was achieved by applying a linear gradient of 0.01--1 [m]{.smallcaps} KCl in RNAP buffer, and the fractions containing RNAP, as determined by SDS-PAGE, were pooled. Dialysis and purification were repeated twice, using a 1-ml HiTrap SP HP cation exchange column followed by a 1-ml HiTrap Q HP anion exchange column (GE Healthcare). Fractions containing enriched holo-RNAP, as determined by SDS-PAGE, were desalted into RNAP buffer containing 10 m[m]{.smallcaps} KCl and concentrated 10-fold using a Vivaspin concentrator (molecular mass cutoff of 5 kDa; Sartorius). The resulting RNAP was then tested in *in vitro* transcription assays (not shown) and stored in 25% glycerol at −80 °C.

For *in vitro* transcription reactions, 0.1--1-kb markers were prepared using Perfect RNA Marker template mix (Novagen). A 20-μl reaction containing 0.75 μg of RNA template mix, 80 m[m]{.smallcaps} HEPES, pH 7.5, 12 m[m]{.smallcaps} MgCl~2~, 10 m[m]{.smallcaps} NaCl, 10 m[m]{.smallcaps} dithiothreitol, 2 m[m]{.smallcaps} ATP, 2 m[m]{.smallcaps} GTP, 2 m[m]{.smallcaps} CTP, 0.1 m[m]{.smallcaps} UTP, 5 μCi of \[α-^32^P\]UTP (800 Ci mmol^−1^, PerkinElmer Life Sciences), 20 units of RiboLock RNase inhibitor (Fermentas), and 50 units of T7 RNAP (Novagen), was incubated for 1 h at 37 °C, before storing at −20 °C. Markers from ∼2 ng of template were used for gel calibration.

The 285-bp region upstream of the *whiB1* gene and the corresponding regions with the altered CRP*^Mt^*-binding sites were excised from plasmids pGS2060, pGS2061, p2225, and p2227 using restriction enzymes XbaI and HindIII. These DNA fragments (0.2 pmol) were incubated for 15 min at 37 °C in a 21-μl reaction volume containing 40 m[m]{.smallcaps} Tris-Cl, pH 8.0, 10 m[m]{.smallcaps} MgCl~2~, 1 m[m]{.smallcaps} dithiothreitol, 75 m[m]{.smallcaps} KCl, 0.1 m[m]{.smallcaps} EDTA, 5% glycerol, 250 μg ml^−1^ bovine serum albumin, 0--2 m[m]{.smallcaps} cAMP, 2 pmol of *M. smegmatis* RNAP, and 0--20 μ[m]{.smallcaps} CRP*^Mt^*. Transcription was initiated by the addition of 4 μl of a solution containing UTP at 50 μ[m]{.smallcaps}; ATP, CTP and GTP at 1 m[m]{.smallcaps}; and 2.5 μCi of \[α-^32^P\]UTP (800 Ci mmol^−1^, PerkinElmer Life Sciences), followed by incubation for 15 min at 37 °C. Reactions were terminated by the addition of 25 μl of Stop/Loading dye solution (95% formamide, 20 m[m]{.smallcaps} EDTA, pH 8, 0.05% bromphenol blue, 0.05% xylene cyanol) containing 0.1--1-kb markers from ∼9.5 ng of template as a loading control. Samples (10 μl) of each reaction were loaded onto a 6% acrylamide, 1× TBE, 8 [m]{.smallcaps} urea gel and analyzed by autoradiography. Autoradiographs were quantified by ImageMaster software (GE Healthcare).

For permanganate footprinting, the *whiB1* promoter fragment was prepared as for electrophoretic mobility shift assay, except that the opposite strand was end-labeled with \[α-^32^P\]dCTP. The resulting radiolabeled DNA (∼20 ng) was incubated at 20 °C for 5 min in a reaction containing 40 m[m]{.smallcaps} Tris-Cl, pH 8.0, 10 m[m]{.smallcaps} MgCl~2~, 75 m[m]{.smallcaps} KCl, 0.1 m[m]{.smallcaps} EDTA, 5% glycerol, 250 μg ml^−1^ bovine serum albumin, 0.1 m[m]{.smallcaps} GTP, 0.1 m[m]{.smallcaps} UTP, 0--2 m[m]{.smallcaps} cAMP, and 0--20 μ[m]{.smallcaps} His-tagged CRP*^Mt^. M. smegmatis* RNAP (2 pmol) was added and incubation continued at 37 °C for 15 min. KMnO~4~ (1 m[m]{.smallcaps}) was added for 10 min at 37 °C, and the reactions were stopped by the addition of 200 μl of 0.3 [m]{.smallcaps} sodium acetate, pH 5.2, containing 20 m[m]{.smallcaps} EDTA, followed by phenol/chloroform extraction and ethanol precipitation. The DNA was then incubated with 10% piperidine at 90 °C for 10 min before being vacuum-dried and resuspended in loading buffer (80% formamide, 0.1% SDS, 10% glycerol, 8 m[m]{.smallcaps} EDTA, 0.1% bromphenol blue, 0.1% xylene cyanol) for electrophoretic fractionation on 6% polyacrylamide-urea gels and autoradiographic analysis. A Maxam and Gilbert G track of the DNA fragment was used to provide a calibration ([@B39]).

RESULTS
=======

### 

#### Cyclic AMP Binding at Two Independent Sites Enhances CRP^Mt^-DNA Interactions

Whereas E. coli CRP is very responsive to cAMP, exhibiting nonspecific low affinity DNA binding in the absence of cAMP ([@B27]), previous reports of the effects of cAMP on the properties of CRP*^Mt^* have been equivocal. Rickman *et al.* ([@B16]) and Bai *et al.* ([@B15]) found significant binding of CRP*^Mt^* to target DNA in the absence of cAMP and only marginal enhancement upon addition of up to 0.1 m[m]{.smallcaps} cAMP. In contrast, Agarwal *et al.* ([@B17]) failed to detect DNA binding in the absence of cAMP, but binding was observed in the presence of 1 m[m]{.smallcaps} cAMP. Others have shown that incubation with cAMP alters intrinsic tryptophan fluorescence ([@B41]) and the polypeptide profiles obtained when CRP*^Mt^* is digested with trypsin ([@B15]), implying that cAMP causes conformational changes in CRP*^Mt^*. To investigate further, we have isolated recombinant His~6~-tagged CRP*^Mt^* by overproduction in a *cyaA* mutant of E. coli, which is unable to synthesize cAMP. This cAMP-free CRP*^Mt^* protein was then used to determine the polypeptide profiles obtained after digestion of CRP*^Mt^* with trypsin in the absence and presence of cAMP ([Fig. 1](#F1){ref-type="fig"}*A*, *lanes 2--7*). In contrast to E. coli CRP, which is relatively resistant to trypsin cleavage in the absence of cAMP ([@B42]), CRP*^Mt^* was readily digested by trypsin, yielding a major polypeptide of molecular mass ∼16 kDa, as estimated by SDS-PAGE ([Fig. 1](#F1){ref-type="fig"}*A*). In the presence of cAMP, the protein was more resistant to proteolysis, and a major polypeptide of molecular mass ∼15 kDa was obtained. In the presence of cGMP, the sensitivity of CRP*^Mt^* to trypsin was similar to that observed in the absence of cAMP, although a different digestion pattern, which included both major polypeptides (∼16 and ∼15 kDa) observed in the absence and presence of cAMP, was obtained suggesting that cGMP is bound by CRP*^Mt^* with concomitant changes in conformation that are different from those invoked by cAMP ([Fig. 1](#F1){ref-type="fig"}*A*, *lanes 10--15*). Significantly, addition of cAMP after preincubation with cGMP for 10 min, or vice versa, resulted in a limited proteolysis pattern identical to that obtained with cAMP alone indicating that cAMP is the preferred ligand ([Fig. 1](#F1){ref-type="fig"}*A*, *lanes 20--24*). To ensure that the presence of the His~6~ tag was not influencing the interaction of CRP*^Mt^* with cAMP, the His~6~ tag was removed by thrombin cleavage, and the partial proteolysis experiments were repeated. This showed that untagged CRP*^Mt^* exhibited the same behavior as the tagged protein in the absence ([supplemental Fig. S1, *lanes 3* and *6*](http://www.jbc.org/cgi/content/full/M109.047720/DC1)) and presence ([supplemental Fig. S1, *lanes 4* and *7*](http://www.jbc.org/cgi/content/full/M109.047720/DC1)) of cAMP suggesting that the His~6~ tag was not affecting the gross conformational changes induced by cAMP binding. Therefore, the His~6~-tagged form of CRP*^Mt^* was considered suitable for further ligand binding studies.

![**Characterization of cAMP binding by CRP*^Mt^*.** *A*, digestion of CRP*^Mt^* (15 μg) by trypsin (1 μg) in the presence and absence of cAMP or cGMP (2 m[m]{.smallcaps}). The composition of the reaction mixtures is indicated *above* each lane of typical Coomassie Blue-stained SDS-polyacrylamide gels. For *lanes 2, 3, 12*, and *13*, the reactions were incubated at 37 °C for 1 min. For all other lanes, the reactions were incubated at 37 °C for 10 min. *Lanes 1, 8, 9*, and *16* are molecular mass markers; the sizes (kDa) of the relevant markers are shown on the *left* (the full set is 250, 150, 100, 75, 50, 37, 25, 20, 15, and 10 kDa, from *top* to *bottom)*. CRP*^Mt^* migrates just above the 25-kDa marker. *Lane 23* shows a reaction in which CRP*^Mt^* was preincubated for 10 min with cGMP before adding cAMP and trypsin, indicated by *cGMP then cAMP. Lane 24* shows a reaction in which CRP*^Mt^* was preincubated for 10 min with cAMP before adding cGMP and trypsin, indicated by *cAMP then cGMP. B*, analysis of cAMP binding by isothermal calorimetry. The *upper panel* shows the raw binding heats. Integrations of these peaks with respect to time and correction to a per mol basis yield the binding isotherm shown in the *lower panel* (*squares*). Also shown in the lower panel (*triangles*) are the heats of ligand dilution.](zbc0111006990001){#F1}

Isothermal calorimetry was used to determine the stoichiometry and affinity of cAMP binding to His~6~-CRP*^Mt^*. A typical titration is shown in [Fig. 1](#F1){ref-type="fig"}*B*. The data yield good nonlinear least squares fitting to a single set of identical binding sites model and are consistent with each protomer of the CRP*^Mt^* dimer binding one cAMP molecule with relatively weak (*K~b~* of ∼1.7 × 10^4^ [m]{.smallcaps}^−1^) affinity. Furthermore, the binding of cAMP is an endothermic reaction (Δ*G~b~* −23.7 kJ mol^−1^) with a positive binding enthalpy (Δ*H~b~* ∼ 30.7 kJ mol^−1^). Therefore, the entropy change *T*Δ*S~b~* is ∼54.4 kJ mol^−1^ K^−1^, and hence cAMP binding is entropically driven. Chemical cross-linking showed that CRP*^Mt^* is a dimer (not shown), and thus the data indicate that unlike the E. coli CRP dimer, the two cAMP-binding sites in the CRP*^Mt^* dimer are independent.

The effect of cAMP binding on the ability of CRP*^Mt^* to bind DNA *in vivo* was tested in the heterologous host E. coli because *M. tuberculosis* has 17 predicted adenylyl cyclase proteins, and E. coli has only one, CyaA; and thus it is possible to simply create a cAMP-free background for these experiments. The parent E. coli strain was a *crp lac* double mutant into which a *cyaA* mutation was introduced. The readout (β-galactosidase activity) from the simple CRP-repressed promoter CCgalΔ4, which contains a consensus CRP site that is recognized by CRP*^Mt^* located such that occupation of this site occludes the promoter ([@B18], [@B34]), was used as a measure of the DNA binding activity of CRP*^Mt^* as shown previously by Spreadbury *et al.* ([@B18]). In the CyaA^+^ and CyaA^−^ strains containing the vector (ptac85), transcription from the reporter was similar (761 ± 24 and 722 ± 25 Miller units, respectively, *n* = 5). However, in the presence of the CRP*^Mt^* expression plasmid (pGS1645), reporter transcription was ∼60% lower (323 ± 86 Miller units, *n* = 5) in the Cya^+^ strain compared with that observed in the absence of CRP*^Mt^*, consistent with the observations of Spreadbury *et al.* ([@B18]). However, in the *cyaA* mutant, which is unable to synthesize cAMP, the readout from the reporter in the presence of CRP*^Mt^* increased by ∼2-fold (613 ± 20 Miller units, *n* = 5) compared with the Cya^+^ strain to reach ∼80% of the activity observed in the absence of CRP*^Mt^*. These data are consistent with cAMP enhancing DNA binding of CRP*^Mt^ in vivo*.

To investigate the effect of cAMP on CRP*^Mt^* DNA binding *in vitro*, preliminary electrophoretic mobility shift assays were used to show that CRP*^Mt^* formed at least two complexes at the *whiB1* promoter in the absence and presence of cAMP but that DNA binding was enhanced in the presence of cAMP ([supplemental Fig. S2*A*](http://www.jbc.org/cgi/content/full/M109.047720/DC1)). Furthermore, in cAMP titration experiments, CRP*^Mt^* binding to the *whiB1* promoter was enhanced when the cAMP concentration exceeded 0.05 m[m]{.smallcaps} (not shown), consistent with the isothermal calorimetry experiments. Moreover, the presence of the His~6~ tag did not significantly affect DNA binding by CRP*^Mt^* in the absence (not shown) and presence of cAMP ([supplemental Fig. S2*B*](http://www.jbc.org/cgi/content/full/M109.047720/DC1)). Thus, the His~6~-tagged form was used in further DNA binding studies.

In summary, the work described above shows the following: (i) that CRP*^Mt^* binds two cAMP molecules per dimer (one per subunit); (ii) that the cAMP-binding sites act independently; and (iii) that cAMP binding induces conformational changes in the CRP*^Mt^* dimer that enhance specific DNA binding *in vitro* and *in vivo*.

#### whiB1 Promoter Contains Two CRP^Mt^-binding Sites

The *whiB1* gene encodes a Wbl (WhiB-like) protein. These proteins have iron-sulfur clusters and are found only in actinomycetes ([@B26]) where they are thought to function as transcription factors and/or as protein-disulfide reductases. The *whiB1* transcript was less abundant in a CRP*^Mt^* mutant ([@B16]), implying that CRP*^Mt^* activates *whiB1* expression, which was confirmed using a *whiB1-lacZ* fusion ([@B17]). 5′-Rapid amplification of cDNA ends was used to confirm that the *whiB1* transcript start was located at 109 or 110 bp upstream of the translational start as reported by Agarwal *et al.* ([@B17]) (data not shown). The electrophoretic mobility shift assays ([supplemental Fig. S2*A*](http://www.jbc.org/cgi/content/full/M109.047720/DC1)) suggested the presence of more than one CRP*^Mt^*-binding site in the *whiB1* promoter. Inspection of the *whiB1* promoter region indicated the presence of two potential CRP*^Mt^*-binding sites upstream of the transcript start ([Fig. 2](#F2){ref-type="fig"}). The first site (CRP1) located at −58.5 relative to the transcript start matches the proposed CRP*^Mt^* consensus (NGTGNNANNNNNCACA) of Rickman *et al.* ([@B16]) in seven of the eight defined bases ([Fig. 2](#F2){ref-type="fig"}). The second potential site (CRP2) is a poorer match to the consensus (six of the eight defined bases are matched) and is located at −37.5 relative to the transcript start. The CRP1 site has previously been implicated in CRP*^Mt^*-dependent activation of *whiB1* expression ([@B17]).

![**Nucleotide sequence of the *whiB1* promoter region (P*whiB1*).** Diagram of the nucleotide sequence of P*whiB1* showing the transcript start (*tsp*) and its associated extended −10 region and −35 region (*underlined*), two CRP*^Mt^*-binding sites (*boxed*), and the ribosome-binding site (*RBS*). The locations of the nucleotides within the CRP*^Mt^*-binding sites that were replaced to impair the sites as indicated in the text are *overlined*.](zbc0111006990002){#F2}

DNase I footprinting showed that both CRP1 and CRP2 sites in the *whiB1* promoter were recognized by CRP*^Mt^* and that binding to both sites was enhanced in the presence of cAMP ([Fig. 3](#F3){ref-type="fig"}*A*). Titration of the *whiB1* promoter with increasing concentrations of CRP*^Mt^* showed that the CRP1 site (−70 to −51) was occupied before the CRP2 site (−50 to −29) ([Fig. 3](#F3){ref-type="fig"}*A*). Furthermore, mutation of CRP1 (indicated by lowercase letters, AGTGAGATAGCCCACG to AGTtAGATAGCCaACG) or CRP2 (CGTAACACTATTGACA to CcaAACACTATTGACA) inhibited binding of CRP*^Mt^* to these sites ([Fig. 3](#F3){ref-type="fig"}*B*). Inactivation of CRP1 also impaired, but did not abolish, binding to CRP2 ([Fig. 3](#F3){ref-type="fig"}*B*, compare *lane 5* with *6*). Thus, it was concluded: (i) the *whiB1* promoter possesses tandem CRP*^Mt^* sites, (ii) binding to these sites is enhanced in the presence of cAMP; and (iii) occupation of CRP2 is improved by occupation of CRP1.

![**Identification of two CRP*^Mt^*-binding sites within P*whiB1*.** *A*, *whiB1* promoter (P*whiB1*) has two CRP*^Mt^*-binding sites. *Lanes 2--6* show reactions in the presence of 2 m[m]{.smallcaps} cAMP; *lanes 7--11* show reactions in the absence of cAMP. *Lane 1* shows no CRP*^Mt^*; *lanes 2* and *7* show 2.5 μ[m]{.smallcaps} CRP*^Mt^*; *lanes 3* and *8* show 5 μ[m]{.smallcaps} CRP*^Mt^*; *lanes 4* and *9* show 10 μ[m]{.smallcaps} CRP*^Mt^*; *lanes 5* and *10* show 25 μ[m]{.smallcaps} CRP*^Mt^*; *lanes 6* and *11* show 50 μ[m]{.smallcaps} CRP*^Mt^*; *lane 12* shows Maxam and Gilbert G track. *WT*, wild type. *B*, mutation of P*whiB1* CRP1 impairs binding of CRP*^Mt^* to CRP2. All reactions contained cAMP (2 m[m]{.smallcaps}). *Lanes 1--4* show reactions of the indicated promoter variants in the absence of CRP*^Mt^* as follows: −*1*, CRP1 site impaired (AGTGAGATAGCCCACG to AGTtAGATAGCCaACG); −*2*, CRP2 site impaired (CGTAACACTATTGACA to CcaAACACTATTGACA), and −*12*, both sites impaired. *Lanes 5--8*, DNase I footprints in the presence of 50 μ[m]{.smallcaps} CRP*^Mt^. Lanes 9--12*, Maxam and Gilbert G tracks. The locations of the CRP1 and CRP2 sites (see [Fig. 2](#F2){ref-type="fig"}) are indicated by *boxes*. The footprints shown are typical of at least three experiments.](zbc0111006990003){#F3}

#### Both CRP^Mt^-binding Sites in the whiB1 Promoter Are Functional

The DNase I footprinting studies indicated that there are two *CRP^Mt^* sites in the *whiB1* promoter. The functionality of the sites was tested by *in vitro* transcription experiments. Transcription from the *whiB1* promoter in the presence of *M. smegmatis* RNAP was low ([Fig. 4](#F4){ref-type="fig"}*A*, *lane 3*). At low concentrations of CRP*^Mt^*, *whiB1* transcription was enhanced, but at higher concentrations CRP*^Mt^* inhibited transcription ([Fig. 4](#F4){ref-type="fig"}*A*, *lanes 4--8*). This same pattern of regulation was observed with the untagged form of CRP*^Mt^* ([supplemental Fig. S3, compare *lanes 3--6* and *lanes 7--10*](http://www.jbc.org/cgi/content/full/M109.047720/DC1)), indicating that the presence of the His~6~ tag does not alter the transcriptional behavior of CRP*^Mt^*. A similar transcription profile was observed in the presence of cAMP ([Fig. 4](#F4){ref-type="fig"}*A*, *lanes 9--16*) except for the following: (i) there was a reproducible decrease in basal transcription ([Fig. 4](#F4){ref-type="fig"}*A*, compare *lanes 3* and *11*), and (ii) the response curve was shifted to the left, with maximum *whiB1* expression occurring in the presence of 1.3 μ[m]{.smallcaps} CRP*^Mt^* in the presence of cAMP compared with 2.5 μ[m]{.smallcaps} CRP*^Mt^* in the absence of cAMP ([Fig. 4](#F4){ref-type="fig"}*B*). This result is consistent with cAMP enhancing CRP*^Mt^* binding to both CRP1 and CRP2 sites in the *whiB1* promoter. In conjunction with the footprinting experiments described above, these data were interpreted to mean that binding to the high affinity CRP1 site activates *whiB1* transcription, whereas occupation of both CRP1 and CRP2 sites inhibits *whiB1* transcription. This conclusion was supported by *in vitro* transcription reactions with *whiB1* promoters carrying mutations in CRP1 and/or CRP2 ([Fig. 4](#F4){ref-type="fig"}*C*). At a low CRP*^Mt^* concentration (2.5 μ[m]{.smallcaps}) in the absence of cAMP, the footprinting evidence indicates that CRP1 will be occupied at the wild-type promoter. Under these conditions, mutation of the CRP1 site decreased transcription of *whiB1* ([Fig. 4](#F4){ref-type="fig"}, *C* and *D*, *lanes 1* and *2*). Under the same conditions, mutation of CRP2 slightly enhanced *whiB1* transcription ([Fig. 4](#F4){ref-type="fig"}, *C* and *D*, *lanes 1* and *3*). A similar pattern was observed in the presence of cAMP ([Fig. 4](#F4){ref-type="fig"}, *C* and *D*, *lanes 5--7*). At a higher CRP*^Mt^* concentration (20 μ[m]{.smallcaps}), the footprints indicate that both CRP1 and CRP2 will be occupied. Under these conditions, impairment of CRP1 had little effect on transcription compared with the wild-type promoter, *i.e.* transcription remained low ([Fig. 4](#F4){ref-type="fig"}, *C* and *D*, *lanes 9* and *10* and *lanes 13* and *14*). However, impairment of CRP2 enhanced transcription of *whiB1* compared with the wild-type promoter under these conditions ([Fig. 4](#F4){ref-type="fig"}, *C* and *D*, *lanes 9* and *11*, and *lanes 13* and *15*). Hence, these observations suggest that occupation of CRP2 is sufficient to repress basal transcription from P*whiB1*. In the presence of cAMP, mutation of both CRP*^Mt^* sites resulted in transcription similar to that of the unaltered promoter in the absence of CRP*^Mt^* ([Fig. 4](#F4){ref-type="fig"}, *C* and *D*, *lanes 8* and *16*). In the absence of cAMP, transcription from the *whiB1* promoter with both CRP1 and CRP2 impaired was lower than from the unaltered promoter in the absence of CRP*^Mt^*, suggesting that in the absence of cAMP there is still some unproductive interaction between CRP*^Mt^* and the altered *whiB1* promoter despite the impairment of both CRP-binding sites ([Fig. 4](#F4){ref-type="fig"}, *C* and *D*, *lanes 4* and *12*). Note that transcription in the absence of CRP*^Mt^* for all the altered promoters was the same as that for the unaltered *whiB1* promoter, indicating that the changes to the sequences of the CRP sites had not affected the basal level of transcription (data not shown).

![***In vitro*** **transcription from P*whiB1* is activated by CRP*^Mt^* occupation of CRP1 and inhibited by CRP*^Mt^* occupation of CRP2.** Reactions were carried out as described under "Experimental Procedures" with the amounts of CRP*^Mt^* used shown *below* each lane. *A*, typical autoradiograph showing the effects of increasing concentrations of CRP*^Mt^* on *whiB1* transcription *in vitro. B*, using the control as the standard, the relative amount of *whiB1* transcript in each of the reactions shown in *A* was quantified and plotted as a *histogram. Open bars*, no cAMP; *filled bars*, 2 m[m]{.smallcaps} cAMP. *C*, *autoradiograph* showing the effects of mutation of the *whiB1* CRP*^Mt^*-binding sites on transcription. The *whiB1* promoter variants are as described in [Fig. 3](#F3){ref-type="fig"}*B*. The control and the *whiB1* transcript are indicated. WT, wild type. *D*, using the amount of transcript formed in the absence of CRP*^Mt^* as the base line, the amount of transcript formed under the indicated conditions was quantified and plotted as a *histogram* (*black bars*, wild-type promoter; *gray bars*, CRP1 impaired; *stippled bars*, CRP2 impaired; *open bars*, CRP1 and CRP2 impaired). The *in vitro* transcriptions shown are typical of at least three experiments. The amount of transcription relative to that observed in the absence of CRP*^Mt^* was calculated by dividing the mean of the test condition by that measured in the absence of CRP*^Mt^* and expressing this value as a fold difference.](zbc0111006990004){#F4}

The *in vitro* transcription experiments showed that CRP*^Mt^* acts as both an activator (at low concentrations) and repressor (at high concentrations) of *whiB1* expression. Permanganate footprinting to detect open complex formation showed the presence of quantitatively similar distortions of DNA at nucleotide T −8 in the *whiB1* promoter mediated by RNAP in the presence or absence of 2.5 μ[m]{.smallcaps} CRP*^Mt^* ([Fig. 5](#F5){ref-type="fig"}*A*, *lanes 3, 4, 8*, and *9*). This evidence suggests that CRP*^Mt^*-mediated activation of *whiB1* expression probably occurs after open complex formation, because in the absence of CRP*^Mt^* transcription from the *whiB1* promoter is low ([Fig. 4](#F4){ref-type="fig"}*A*, compare *lanes 3* and *4*). In the presence of 20 μ[m]{.smallcaps} CRP*^Mt^*, the open complex was not detected ([Fig. 5](#F5){ref-type="fig"}*A*, *lanes 5* and *10*) indicating that higher concentrations of CRP*^Mt^* inhibit *whiB1* expression at a point before open complex formation, probably by inhibiting RNAP binding.

![***M. tuberculosis*** **CRP activates *whiB1* transcription after open complex formation.** *A*, permanganate footprints were obtained with P*whiB1* in the presence and absence of *M. smegmatis* RNAP and CRP*^Mt^. Lanes 1* and *6* show CRP*^Mt^* 2.5 μ[m]{.smallcaps} only; *lanes 2* and *7* show CRP*^Mt^* 20 μ[m]{.smallcaps} only; *lanes 3* and *8* show RNAP only; *lanes 4* and *9* show RNAP plus CRP*^Mt^* 2.5 μ[m]{.smallcaps}; *lanes 5* and *10* show RNAP plus CRP*^Mt^* 20 μ[m]{.smallcaps}; *lane 11* shows Maxam and Gilbert G track. *Lanes 1--5* show reactions in the absence of cAMP; *lanes 6--10* show reactions in the presence of cAMP (2 m[m]{.smallcaps}). The location of the −10 element is indicated. *B*, DNase I footprint of P*whiB1* in the presence of an activating concentration of CRP*^Mt^* (2.5 μ[m]{.smallcaps}) and RNAP. *Lanes 1* and *2* show no protein; *lanes 3* and *4* show CRP*^Mt^*; *lanes 5* and *6* show CRP*^Mt^* plus RNAP; *lane 7* shows Maxam and Gilbert G track. The locations of the CRP1 (protected) and CRP2 (unprotected) sites are indicated by *filled rectangles*, as is the region of protection afforded by RNAP. The location of the −10 element is also marked. The hypersensitive site within CRP2 that appears in the presence of RNAP is indicated by the *arrow*. The footprints shown are typical of at least three experiments.](zbc0111006990005){#F5}

DNase I footprinting of the *whiB1* promoter in the presence of *M. smegmatis* RNAP and activating concentrations of CRP*^Mt^* (2.5 μ[m]{.smallcaps}) showed that RNAP could bind at the promoter when the CRP1 site was occupied and that this was accompanied by the appearance of an RNAP-dependent hypersensitive site at position −34, which is within the CRP2 site ([Fig. 5](#F5){ref-type="fig"}*B*). The presence of the hypersensitive site is attributed to docking of the C-terminal domain of the RNAP α-subunit downstream of CRP*^Mt^* bound at CRP1.

To determine whether the effects of CRP*^Mt^* on *whiB1* transcription observed *in vitro* were also apparent *in vivo*, a promoter fusion containing DNA from −187 to 129 relative to the transcript start was fused upstream of a *lac* reporter gene, and transcription was estimated in *M. tuberculosis* wild-type H37Rv and an isogenic *Rv3676* (*crp*) mutant ([Fig. 6](#F6){ref-type="fig"}). Under exponential growth conditions, expression of *whiB1* was decreased by ∼3-fold in the CRP*^Mt^* mutant (ΔRv3676), consistent with CRP*^Mt^*-dependent activation. An ∼5-fold reduction in expression was observed when the CRP1 site was disabled, reflecting the absence of activation from CRP1 but retention of repression from CRP2. Accordingly, mutation of CRP2, without disrupting the −35 element (underlined) of the *whiB1* promoter (CGTAACACTA[TTGACA]{.ul} to CcaAACACTA[TTGACA]{.ul}), resulted in a small but reproducible increase in *whiB1* expression. Similarly, improvement of the CRP2 site (CGTAACACTATTGACA to CGTgACACTATTGACA) caused a reproducible decrease in *whiB1* expression. Disabling both CRP1 and CRP2 lowered β-galactosidase activities by an amount similar to that observed using the unaltered promoter in the *crp* mutant. The *in vivo* data correlated well with the *in vitro* transcription data as shown in [Fig. 4](#F4){ref-type="fig"}, *C* and *D*. Thus, when 2.5 μ[m]{.smallcaps} CRP*^Mt^* was used in the *in vitro* transcription reactions ([Fig. 4](#F4){ref-type="fig"}*D*), the fold changes in transcription upon impairment of CRP-binding sites compared with the unaltered promoter were as follows: −3.5 to −2.4 when CRP1 was impaired; +1.2 to +1.6 when CRP2 was impaired; and −2.6 to −2.0 when both CRP1 and CRP2 were impaired. These values are similar to those obtained for transcription *in vivo* ([Fig. 6](#F6){ref-type="fig"}) as follows: −4.6 when CRP1 was impaired; +1.2 when CRP2 was impaired; and −2.0 when CRP1 and CRP2 were impaired. Hence, the *in vitro* and *in vivo* experiments are consistent with a mechanism in which occupation of CRP1 enhances *whiB1* expression, whereas occupation of both CRP1 and CRP2 or of CRP2 alone represses *whiB1* expression in *M. tuberculosis*.

![**Patterns of *whiB1* expression *in vivo* match those seen *in vitro*.** β-Galactosidase assays were performed on cell extracts from *M. tuberculosis* H37Rv strains containing constructs with P*whiB*1 promoter linked to the *lacZ* reporter gene. These were as follows: the unaltered P*whiB1* (wild-type), P*whiB1* with the CRP1 site impaired (*CRP1 impaired*), P*whiB1* with the CRP2 site impaired (*CRP2 impaired*), and P*whiB1* with both the CRP1 and CRP2 sites impaired (*CRP1 and 2 impaired*). The effects of the mutations made in the CRP sites are shown as expression relative to that of the unaltered wild-type promoter to allow direct comparison with the *in vitro* transcription assays in [Fig. 4](#F4){ref-type="fig"}*D*. Thus, the result for P*whiB1* with an impaired CRP1 site is shown as a *gray bar*; the result for P*whiB1* with an impaired CRP2 site is shown as a *stippled bar*, and the result for P*whiB1* with impaired CRP1 and CRP2 sites is shown as an *open bar*. In addition, on the *right* of the figure, the effect of improving the CRP2 site of P*whiB1* (CRP2 improved; *diagonal stripes*) as well as expression from unaltered P*whiB1* in H37Rv ΔRv3676 (wild-type in *crp* mutant strain; *horizontal stripes*) is shown. The values shown are calculated from the mean β-galactosidase activities from three bacterial cultures. All assays were done in triplicate and varied by \<15%. The expression relative to the unaltered *whiB1* promoter in *M. tuberculosis* H37Rv was calculated by dividing the mean of the test condition by that obtained for the wild-type promoter and expressing this value as a fold change.](zbc0111006990006){#F6}

DISCUSSION
==========

The work described here shows that CRP*^Mt^* is a homodimeric protein with one cAMP-binding site per protomer. This conclusion is substantiated by the crystal structure of CRP*^Mt^* bound to cAMP that was published during the review of this manuscript ([@B43]). For E. coli CRP, cAMP binding is cooperative; the first binding event is exothermic and the second is endothermic, and the sensory domain binding sites are saturated by micromolar concentrations of cAMP ([@B44]). This is not the case for CRP*^Mt^* where the cAMP-binding sites are independent. The cAMP binding parameters for CRP*^Mt^* are similar to those for cGMP binding to E. coli CRP, except that the thermodynamic properties of these interactions are opposite; CRP*^Mt^* cAMP binding has a positive enthalpy, whereas E. coli CRP cGMP binding is exothermic ([@B44]). Recently, cAMP binding by E. coli CRP has been shown to reorganize the major helices that form the dimer interface, thereby rotating the DNA binding domains so that they can interact with adjacent major grooves in target DNA ([@B45]). The differences in binding of cAMP by the E. coli and *M. tuberculosis* CRP proteins suggest that the signal transduction pathways that promote site-specific DNA binding might be different, and this might be reflected in the relatively small enhancement in DNA binding caused by addition of cAMP.

Comparison of the cAMP binding pockets of CRP*^Mt^* ([@B44]) and E. coli CRP ([@B46], [@B47]) reveals that most of the side chains that contact cAMP are either conserved or are conservatively substituted. The significant difference between the two proteins, in the context of the independent cAMP binding of CRP*^Mt^* compared with the cooperative cAMP binding of E. coli CRP, is the substitution of Ser-128 in E. coli CRP by Asn in CRP*^Mt^*. Ser-128 makes a cross-subunit contact with cAMP in E. coli CRP; *i.e.* Ser-128 of subunit B interacts with cAMP bound at subunit A ([@B46], [@B47]). [Fig. 7](#F7){ref-type="fig"} shows that the N6 position of cAMP is able to donate two hydrogen bonds, which interact with the acceptor γ oxygen atoms of Thr-127 of one subunit (subunit A) and of Ser-128 in the other subunit (subunit B) in E. coli CRP. The latter two atoms are constrained to act as acceptors because they in turn donate hydrogen bonds to the main chain carbonyl acceptors of residues 123 in subunit A and 124 in subunit B, respectively. Residues 123 and 124 are located in the dimerization helices of the two E. coli CRP subunits. The N6 of the adenosine moiety of cAMP therefore acts via Thr-127 of subunit A and Ser-128 of subunit B as a bridge between the main chains of the dimerization helices of the two subunits ([Fig. 7](#F7){ref-type="fig"}*A*). A reciprocal interaction occurs when cAMP is bound in the other site of the CRP dimer, and hence the cAMP-binding sites of each protomer are connected. In CRP*^Mt^*, the equivalent position to Ser-128 is occupied by Asn-135, and this does not significantly alter the position of cAMP. However, the Asn side chain makes two hydrogen bonds to cAMP; the ND2 of the Asn side chain can donate an H bond to the N7 of cAMP, and the OD1 atom can accept a hydrogen bond from one of the N6 donor hydrogen atoms ([Fig. 7](#F7){ref-type="fig"}*B*). This pattern of interactions removes the possibility of the side chain of Asn-135 donating a hydrogen bond to the main chain carbonyl of residue 131 of subunit B. For this reason, replacement of the Ser by Asn at this position uncouples the cAMP-binding sites in CRP*^Mt^*. Consistent with this interpretation, the substitution of Ser-128 by Ala in E. coli CRP abolishes cooperative cAMP binding ([@B48]).

![**Schematic diagram of hydrogen bonding contacts of the adenine groups of cAMP in the binding pockets of E. coli and *M. tuberculosis* CRP proteins.** *A*, observed hydrogen bonds between cAMP and E. coli CRP (Protein Data Bank code [2cgp](2cgp)) ([@B45]). *B*, predicted hydrogen bonds between cAMP and CRP*^Mt^* in which Ser-128 is replaced by Asn. Hydrogen bonds are shown as *dotted arrows* from donor to acceptor. Atoms referred to in the text are labeled.](zbc0111006990007){#F7}

Although cAMP enhanced binding of recombinant CRP*^Mt^* to target DNA, this enhancement was not comparable with that observed with E. coli CRP, where DNA-binding affinity is enhanced by several orders of magnitude in the presence of 0.1 m[m]{.smallcaps} cAMP, allowing specific DNA binding at nanomolar concentrations ([@B27], [@B48]). For CRP*^Mt^*, a much less significant enhancement of DNA binding was observed, and higher concentrations of cAMP compared with E. coli CRP were required. This may point to meaningful physiological changes in cAMP concentration in *M. tuberculosis* occurring at higher levels than those in E. coli. Indeed, cAMP concentrations in mycobacteria have been reported to be rather high ([@B49]), being ∼100--200-fold greater than for E. coli. The high intracellular concentration of cAMP in *M. tuberculosis* is consistent with the numerous adenylyl cyclases synthesizing cAMP. This and the reported increase in cAMP levels that occurs after infection of macrophages by pathogenic mycobacteria ([@B5][@B6][@B7]) point to cAMP being an important signaling molecule in infection. The evidence presented here suggests that, perhaps as a consequence of the high intracellular concentrations of cAMP in *M. tuberculosis*, CRP*^Mt^* has evolved a different mode of interaction with cAMP compared with the E. coli paradigm, involving low affinity binding of cAMP to independent sites. Nevertheless, the response of CRP*^Mt^* to cAMP was very significant for expression of *whiB1*.

Several different classes of regulated bacterial promoters have been identified based on the locations of the binding sites for transcription activators. Promoters dependent on transcription factors bound at or close to −61 are known as class I promoters ([Fig. 8](#F8){ref-type="fig"}). At these promoters a specific region, known as activating region 1 (AR1), of the transcription factor interacts with the C-terminal domain of the α-subunit (α-CTD) of RNAP to activate transcription. A common alternative architecture is that of the class II promoters, in which the transcription factor binds to a site that overlaps the core −35 element of the promoter. At class II promoters multiple interactions between the transcription factor and RNAP are possible, including an AR1 interaction with α-CTD, an AR2 interaction with the RNAP α-subunit N-terminal domain, and interaction between AR3 and the σ-subunit of RNAP ([Fig. 8](#F8){ref-type="fig"}). Class III promoters have transcription factors bound in tandem making both class I- and class II-type interactions with RNAP ([Fig. 8](#F8){ref-type="fig"}). The experiments described here and elsewhere show that expression of *whiB1* is dependent on CRP*^Mt^* and that this requires a CRP*^Mt^*-binding site centered 58.5 bp upstream of the transcript start, a class I location ([@B16], [@B17]). However, it is now shown that there is a second, lower affinity, negatively acting CRP-binding site (CRP2 centered at −37.5) located immediately downstream of CRP1 that has significant implications for cAMP-CRP*^Mt^*-mediated regulation of *whiB1* expression. The identification of a second class II CRP*^Mt^*-binding site (CRP2) that is occupied when cAMP levels increase and inhibits *whiB1* activation by CRP*^Mt^* bound at the class I site (CRP1) indicates that *whiB1* expression *in vivo* should be maximal at intermediate cAMP concentrations. Hence, the following model for cAMP-responsive *whiB1* expression provides the simplest explanation for the data described here. The locations of the two CRP*^Mt^*-binding sites (−58.5 and −37.5) are such (centers of the sites are separated by 21 bp) that they are located on the same face of the DNA helix. At low concentrations of the CRP*^Mt^*-cAMP complex, CRP1 is preferentially occupied ([Fig. 3](#F3){ref-type="fig"}*A*); the α-CTD of RNAP docks downstream of CRP1 ([Fig. 5](#F5){ref-type="fig"}*B*), and transcription of *whiB1* is activated via a class I mechanism ([Fig. 8](#F8){ref-type="fig"}). Activation of class I promoters by E. coli CRP occurs solely by recruiting RNAP to the promoter by increasing the binding constant for the formation of the RNAP-promoter closed complex (reviewed in Ref. [@B10]). However, the permanganate footprints suggest that low (nonrepressing; [Fig. 4](#F4){ref-type="fig"}*A*) concentrations of CRP*^Mt^* or CRP*^Mt^*-cAMP do not significantly enhance open complex formation at the *whiB1* promoter compared with reactions lacking CRP*^Mt^* ([Fig. 5](#F5){ref-type="fig"}*A*) indicating that a step after open complex formation is activated. Further experimental work will be needed to identify the mechanism by which this is achieved.

![**Architecture of CRP-dependent promoters.** The diagram shows the arrangement of nucleoprotein complexes formed at typical class I, class II, and class III CRP-dependent promoters. At class I promoters, the center of the CRP dimer (shown in ribbon form) is positioned at −61.5, −71.5, −81.5, or −91.5 upstream of the transcript start, placing it on the same face of the DNA helix (*horizontal line*) as RNAP (shown as *unfilled ellipses*). This arrangement allows the C-terminal domain of the RNAP α-subunit (α-CTD) to interact directly with activating region 1 (*AR1*) of the downstream subunit of the CRP dimer (♦). At class II promoters, the CRP dimer is centered at or close to −41.5 and is again on the same face of the DNA helix as RNAP. At these promoters multiple interactions between CRP and RNAP are possible, with contacts between AR1 of the upstream subunit of the CRP dimer and α-CTD, and between activating region 2 (AR2) of the downstream subunit of the CRP dimer and the N-terminal domain of the RNAP α-subunit (α-*NTD*; ■), and activating region 3 (*AR3*) of the same CRP subunit and the RNAP σ factor (★). Class III promoters have tandem CRP sites in class I and class II locations allowing AR1, AR2, and AR3 contacts with RNAP. For E. coli CRP, these protein-protein interactions recruit RNAP to CRP-dependent promoters ([@B10]). For *M. tuberculosis* P*whiB1* at low cAMP-CRP*^Mt^* concentrations, CRP1 is occupied and expression is activated, not by RNAP recruitment but by enhancing a step after open complex formation, *i.e.* promoter clearance. At high cAMP-CRP*^Mt^* concentrations, CRP1 and CRP2 are occupied. This arrangement has some similarities with the class III architecture, but because the CRP1 and CRP2 sites are immediately adjacent, there is insufficient space to accommodate the α-CTD between the tandem CRP dimers resulting in inhibition of transcription by preventing α-CTD from docking with DNA thereby inhibiting productive interaction of RNAP with P*whiB1* (indicated by the *double-headed arrow*).](zbc0111006990008){#F8}

At higher CRP*^Mt^* or CRP*^Mt^*-cAMP concentrations, both CRP1 (class I position) and CRP2 (class II position) are occupied ([Fig. 3](#F3){ref-type="fig"}*A*). Occupation of both CRP1 and CRP2 sites would leave little space between the two CRP*^Mt^* dimers, preventing the formation of a typical class III nucleoprotein complex and thus the RNAP α-CTD is displaced, which is likely to result in either poor or unproductive binding of RNAP to the *whiB1* promoter ([Fig. 8](#F8){ref-type="fig"}). In this way, occupation of CRP2 by CRP*^Mt^* antagonizes activation by CRP*^Mt^* bound at CRP1 resulting in inhibition of *whiB1* transcription. Because the concentration of cAMP in *M. tuberculosis* increases during infection of macrophages ([@B5], [@B7]), this suggests that *whiB1* might be expressed transiently during infection. Although the available microarray datasets ([@B50], [@B51]) do not suggest that *whiB1* expression responds transiently at the time points sampled, this study indicates that the possibility that *whiB1* is transiently expressed during infection should be tested by obtaining high resolution long time course gene expression data to determine the significance of any such transient expression for *M. tuberculosis* pathogenesis.
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